Regeneron Pharmaceuticals, Inc.

(NASDAQ Global Select)
Back to all articles
Neutral +3

Regeneron to Report First Quarter 2026 Financial and Operating Results and Host Conference Call and Webcast on April 29, 2026

AI-generated analysis

📅 Regeneron Pharmaceuticals announced it will report its first quarter 2026 financial results on Wednesday, April 29, 2026.

🕒 The earnings call and webcast are scheduled for 8:30 AM Eastern Time before U.S. market open.

💻 Investors can access the live webcast via the 'Investors and Media' page on Regeneron's official website.

📞 Participants must register in advance to join via telephone to receive a dial-in number and unique passcode.

🗂 A replay and transcript of the event will be archived on the Company’s website for at least 30 days.

🏢 Regeneron is a leading biotechnology company founded and led by physician-scientists focused on translating science into medicine.

🔬 The company uses proprietary technologies like VelociSuite® to optimize fully human antibodies and bispecific antibody classes.

💊 Its pipeline targets serious diseases including eye, inflammatory, cancer, neurological, cardiovascular, and rare conditions.

🧬 The Regeneron Genetics Center® provides data-powered insights for identifying innovative genetic medicine targets.

🌐 For additional information, stakeholders can visit www.Regeneron.com or follow the company on social media platforms.

📞 Investor relations contacts are Ryan Crowe and Christina Chan at 914.847.8790 or via provided email addresses.

⚠️ This press release was published by GLOBE NEWSWIRE on March 25, 2026, from Tarrytown, N.Y.

📈 Recent news snippets indicate ongoing analyst activity with Goldman Sachs issuing a buy rating and Wells Fargo raising the price target to $825.

✅ Dupixent® recently received approval in Japan as the first targeted medicine to treat adults with bullous pemphigoid.

⏳ Related market events include an upcoming 'Triple-Witching' event scheduled for Friday mentioned in recent commentary.

Bullish Signals
  • Regeneron is a leading biotechnology company that consistently translates science into medicine, resulting in numerous approved treatments and product candidates in development.
  • The company utilizes proprietary technologies like VelociSuite® to produce optimized fully human antibodies and new classes of bispecific antibodies, advancing drug discovery and development capabilities.
  • Dupixent® has received approval in Japan as the first targeted medicine to treat adults with bullous pemphigoid, marking a significant milestone for the company's commercial portfolio.
Risk Factors
  • The article contains no negative information or risk factors, as it is a standard pre-earnings press release announcing a conference call and webcast date.
  • All related content in the provided text, including analyst upgrades from Goldman Sachs and Wells Fargo, represents positive sentiment rather than downside risks.
Full Analysis
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) has announced its schedule for reporting first quarter 2026 financial and operating results, set for release on Wednesday, April 29, 2026, before the opening of U.S. financial markets. In conjunction with the earnings report, the company will host a conference call and simultaneous webcast at 8:30 AM Eastern Time. Investors and media can access the live webcast through the 'Investors and Media' page on Regeneron's website, while telephone participants must register in advance to receive dial-in details, including confirmation emails with passcodes and registrant IDs. Replays and transcripts of the call will be archived on the Company's website for a minimum of 30 days. Founded and led by physician-scientists based in Tarrytown, N.Y., Regeneron describes itself as a leading biotechnology company that invents, develops, and commercializes life-transforming medicines for serious diseases. The firm emphasizes its unique ability to consistently translate science into medicine, with most of its approved treatments and product candidates being homegrown within its laboratories. The Company's portfolio targets various therapeutic areas including eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, neurological diseases, hematologic conditions, infectious diseases, and rare diseases. Regeneron leverages proprietary technologies such as VelociSuite®, which produces optimized fully human antibodies and new classes of bispecific antibodies, to push the boundaries of scientific discovery and accelerate drug development. Additionally, the company utilizes data-powered insights from the Regeneron Genetics Center® to identify innovative targets and complementary approaches aimed at treating or curing diseases. The Company's corporate communications are managed by Ryan Crowe and Christina Chan, who can be reached via phone or email for investor relations inquiries.